PharmaCyte Biotech, Inc.
For the period ended Jan 31, 2026. Filed Mar 17, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jan 31, 2026 · Filed Mar 17, 2026
PMCB$0.40-1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Condensed Consolidated Financial Statements (Unaudited)
CONDENSED CONSOLIDATED BALANCE SHEETS
| (Unaudited) | ||
|---|---|---|
| January 31, 2026 | April 30, 2025 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $20,165,535 | $15,172,163 |
| Marketable equity securities | 372,251 | 366,316 |
| Warrant asset – QCLS - current | – | 2,917,000 |
| Convertible Note receivable – Femasys - current | – | 3,696,000 |
| Prepaid expenses and other current assets | 158,664 | 223,759 |
| Total current assets | 20,696,450 | 22,375,238 |
| Other assets: | ||
| Intangible asset | 1,549,427 | 1,549,427 |
| Investment in preferred stock – QCLS | 22,472,000 | 22,474,000 |
| Warrant asset – QCLS – non current | 10,242,000 | 5,701,000 |
| Warrant asset – Femasys | 906,000 | 3,061,000 |
| Other assets | 7,688 | 7,688 |
| Total other assets | 35,177,115 | 32,793,115 |
| Total Assets | $55,873,565 | $55,168,353 |
| LIABILITIES, TEMPORARY EQUITY AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $1,200,082 | $399,204 |
| Accrued expenses | 445,656 | 2,515,080 |
| Accrued Series C dividends | 32,491 | – |
| Total current liabilities | 1,678,229 | 2,914,284 |
| Other liabilities: | ||
| Long-term portion of accrued expenses | – | 25,000 |
| Warrant liabilities | 13,657,000 | 338,000 |
| Derivative liabilities | 1,136,000 | – |
| Total other liabilities | 14,793,000 | 363,000 |
| Total Liabilities | 16,471,229 | 3,277,284 |
| Commitments and Contingencies (Note 8) | – | |
| Temporary Equity: | ||
| Series B convertible preferred stock: authorized 35,000 shares, $0.0001 par value and $1,000 face value, 0 shares issued and outstanding as of January 31, 2026 and April 30, 2025, respectively | – | – |
| Series C convertible preferred stock: authorized 7,000 shares, $0.0001 par value and $1,000 face value, 4,766 and 0 shares issued and outstanding as of January 31, 2026 and April 30, 2025, respectively. Liquidation preference of $4,765,671 as of January 31, 2026. | 872,323 | – |
| Contingently redeemable warrants | 417,000 | – |
| Total temporary equity | 1,289,323 | – |
| Stockholders’ equity: | ||
| Series A preferred stock: authorized 1 share, $0.0001 par value and 0 shares issued and outstanding as of January 31, 2026 and April 30, 2025 | – | – |
| Common stock: authorized 200,000,000 shares, $0.0001 par value; 26,005,715 and 21,672,095 shares issued and 10,735,649 and 6,795,779 shares outstanding as of January 31, 2026 and April 30, 2025, respectively. | 2,602 | 2,167 |
| Additional paid-in capital | 183,141,663 | 181,489,647 |
| Accumulated deficit | (100,000,171) | (84,968,960) |
| Treasury stock, at cost, 15,270,066 and 14,876,316 shares as of January 31, 2026, and April 30, 2025, respectively. | (45,009,541) | (44,607,916) |
| Accumulated other comprehensive loss | (21,540) | (23,869) |
| Total stockholders’ equity | 38,113,013 | 51,891,069 |
| Total Liabilities, Temporary Equity and Stockholders’ Equity | $55,873,565 | $55,168,353 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
| Three Months Ended January 31, | Nine Months Ended January 31, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenue | $– | $– | $– | $– |
| Operating expenses: | ||||
| Research and development costs | 93,113 | 118,196 | 329,355 | 311,682 |
| General and administrative | 2,024,989 | 842,056 | 4,013,103 | 3,024,316 |
| Total operating expenses | 2,118,102 | 960,252 | 4,342,458 | 3,335,998 |
| Loss from operations | (2,118,102) | (960,252) | (4,342,458) | (3,335,998) |
| Other income (expenses): | ||||
| Interest income | 230,668 | 255,692 | 654,848 | 1,185,686 |
| Change in fair value of warrant liability | 1,895,865 | 4,487,000 | (8,335,135) | 8,400,000 |
| Change in fair value of derivative liability | 557,000 | – | 859,000 | 2,184,000 |
| Change in fair value of convertible note receivable - Femasys | – | (79,000) | 1,304,000 | 601,000 |
| Change in fair value of warrant asset - Femasys | (214,000) | (596,000) | (2,155,000) | (1,830,000) |
| Change in fair value of investment - QCLS | 1,725,000 | (3,031,000) | (3,485,000) | (1,642,050) |
| Change in fair value of warrants - QCLS | (1,200,000) | (3,194,000) | 18,000 | (8,123,684) |
| Gain on legal settlement – re-fair value of warrants | – | – | 106,000 | – |
| Gain on related party investment - QCLS | – | – | 2,089,000 | 21,395,734 |
| Issuance costs – Series C convertible preferred stock and warrants | – | – | (1,234,553) | – |
| Loss on issuance of Series C convertible preferred stock | – | – | (215,000) | – |
| Unrealized loss on marketable securities | (128,939) | 72,632 | (294,065) | 72,632 |
| Other expense | (632) | (400) | (848) | (852) |
| Total other income and (expense), net | 2,864,962 | (2,085,076) | (10,688,753) | 22,242,466 |
| Net income (loss) | 746,860 | (3,045,328) | (15,031,211) | 18,906,468 |
| Preferred stock dividends | (98,458) | – | (195,097) | (1,129,759) |
| Preferred stock accretion | (2,204,657) | – | (3,106,653) | (3,193,404) |
| Net income (loss) attributable to common stockholders | $(1,556,255) | $(3,045,328) | $(18,332,961) | $14,583,305 |
| Basic and diluted income (loss) per share attributable to common stockholders | $(0.17) | $(0.44) | $(2.41) | $1.67 |
| Weighted average shares outstanding basic and diluted | 9,262,829 | 6,960,014 | 7,618,128 | 7,487,813 |
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
| Three Months Ended January 31, | Nine Months Ended January 31, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Net income (loss) | $746,860 | $(3,045,328) | $(15,031,211) | $18,906,468 |
| Other comprehensive income (loss): | ||||
| Foreign currency translation | 2,587 | (1,219) | 2,329 | (975) |
| Other comprehensive income (loss) | 2,587 | (1,219) | 2,329 | (975) |
| Comprehensive income (loss) | $749,447 | $(3,046,547) | $(15,028,882) | $18,905,493 |
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN TEMPORARY EQUITY AND STOCKHOLDERS’ EQUITY
THREE AND NINE MONTHS ENDED JANUARY 31, 2026 AND 2025
| Preferred Stock Series B · Preferred Stock Series C · Contingently Redeemable Warrants · Common Stock · Additional Paid-in · Treasury Stock · Accumulated · Accumulated Other Comprehensive · Total Stockholders’ | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Amount | Shares | Amount | Capital | Shares | Amount | Deficit | Loss | Equity | |
| Balance, April 30, 2024 | 14,646 | $11,867,016 | – | $– | $– | 21,672,078 | $2,167 | $185,334,173 | (13,634,454) | $(42,040,216) | $(115,625,010) | $(23,511) | $27,647,603 |
| Stock-based compensation options | – | – | – | – | – | – | – | 222,677 | – | – | – | – | 222,677 |
| Preferred stock accretion | – | 2,148,047 | – | – | – | – | – | (2,148,047) | – | – | – | – | (2,148,047) |
| Series B preferred stock redemption | (2,917) | (2,893,144) | – | – | – | – | – | – | – | – | – | – | – |
| Series B preferred stock subject to redemption | (5,833) | (5,788,805) | – | – | – | – | – | – | – | – | – | – | – |
| Preferred stock dividends | – | – | – | – | – | – | – | (685,801) | – | – | – | – | (685,801) |
| Foreign currency translation adjustment | – | – | – | – | – | – | – | – | – | – | – | 183 | 183 |
| Net income | – | – | – | – | – | – | – | – | – | – | 23,421,355 | – | 23,421,355 |
| Repurchase of common stock | – | – | – | – | – | – | – | – | (320,346) | (749,600) | – | – | (749,600) |
| Balance, July 31, 2024 | 5,896 | 5,333,114 | – | – | – | 21,672,078 | 2,167 | 182,723,002 | (13,954,800) | (42,789,816) | (92,203,655) | (23,328) | 47,708,370 |
| Fractional shares adjustment | – | – | – | – | – | 17 | – | – | – | – | – | – | – |
| Stock-based compensation options | – | – | – | – | – | – | – | 119,155 | – | – | – | – | 119,155 |
| Preferred stock accretion | – | 1,045,357 | – | – | – | – | – | (1,045,357) | – | – | – | – | (1,045,357) |
| Series B preferred stock redemption | (2,917) | (2,868,607) | – | – | – | – | – | – | – | – | – | – | – |
| Series B preferred stock subject to redemption | (2,979) | (3,509,864) | – | – | – | – | – | – | – | – | – | – | – |
| Preferred stock dividends | – | – | – | – | – | – | – | (443,958) | – | – | – | – | (443,958) |
| Foreign currency translation adjustment | – | – | – | – | – | – | – | – | – | – | – | 61 | 61 |
| Net loss | – | – | – | – | – | – | – | – | – | – | (1,469,560) | – | (1,469,560) |
| Repurchase of common stock | – | – | – | – | – | – | – | – | (683,036) | (1,417,565) | – | – | (1,417,565) |
| Balance, October 31, 2024 | – | – | – | – | – | 21,672,095 | 2,167 | 181,352,842 | (14,637,836) | (44,207,381) | (93,673,215) | (23,267) | 43,451,146 |
| Stock-based compensation options | – | – | – | – | – | – | – | 72,861 | – | – | – | – | 72,861 |
| Foreign currency translation adjustment | – | – | – | – | – | – | – | – | – | – | – | (1,219) | (1,219) |
| Net loss | – | – | – | – | – | – | – | – | – | – | (3,045,328) | – | (3,045,328) |
| Repurchase of common stock | – | – | – | – | – | – | – | – | (129,365) | (227,275) | – | – | (227,275) |
| Balance, January 31, 2025 | – | $– | – | $– | $– | 21,672,095 | $2,167 | $181,425,703 | (14,767,201) | $(44,434,656) | $(96,718,543) | $(24,486) | $40,250,185 |
(continued)
| Preferred Stock Series B · Preferred Stock Series C · Contingently Redeemable Warrants · Common Stock · Additional Paid-in · Treasury Stock · Accumulated · Accumulated Other Comprehensive · Total Stockholders’ | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Amount | Shares | Amount | Capital | Shares | Amount | Deficit | Loss | Equity | |
| Balance, April 30, 2025 | – | $– | – | $– | $– | 21,672,095 | $2,167 | $181,489,647 | (14,876,316) | $(44,607,916) | $(84,968,960) | $(23,869) | $51,891,069 |
| Stock-based compensation options | – | – | – | – | – | – | – | 60,492 | – | – | – | – | 60,492 |
| Foreign currency translation adjustment | – | – | – | – | – | – | – | – | – | – | – | 123 | 123 |
| Net income | – | – | – | – | – | – | – | – | – | – | (8,360,096) | – | (8,360,096) |
| Balance, July 31, 2025 | – | – | – | – | – | 21,672,095 | 2,167 | 181,550,139 | (14,876,316) | (44,607,916) | (93,329,056) | (23,746) | 43,591,588 |
| Stock-based compensation options | – | – | – | – | – | – | – | 60,492 | – | – | – | – | 60,492 |
| Issuance of Series C preferred stock and warrants, net of transaction costs | – | – | 7,000 | – | 417,000 | – | – | – | – | – | – | – | – |
| Series C Preferred stock accretion | – | – | – | 901,996 | – | – | – | (901,996) | – | – | – | – | (901,996) |
| Series C preferred stock dividend subject to settlement | – | – | – | (96,639) | – | – | – | – | – | – | – | – | – |
| Series C preferred stock dividends accrual | – | – | – | 96,639 | – | – | – | (96,639) | – | – | – | – | (96,639) |
| Foreign currency translation adjustment | – | – | – | – | – | – | – | – | – | – | – | (381) | (381) |
| Net loss | – | – | – | – | – | – | – | – | – | – | (7,417,975) | – | (7,417,975) |
| Balance, October 31, 2025 | – | – | 7,000 | 901,996 | 417,000 | 21,672,095 | 2,167 | 180,611,996 | (14,876,316) | (44,607,916) | (100,747,031) | (24,127) | 35,235,089 |
| Stock-based compensation options | – | – | – | – | – | – | – | 60,492 | – | – | – | – | 60,492 |
| Stock issued upon vesting of restricted stock units | – | – | – | – | – | 875,000 | 89 | 892,411 | (393,750) | (401,625) | – | – | 490,875 |
| Stock issued for warrant exercises | – | – | – | – | – | 1,100,000 | 110 | 1,645,785 | – | – | – | – | 1,645,895 |
| Preferred stock accretion | – | – | 2,204,657 | – | – | – | (2,204,657) | – | – | – | – | (2,204,657) | |
| Series C preferred stock redeemed | – | – | (2,234) | (2,234,330) | – | 2,358,620 | 236 | 2,234,094 | – | – | – | – | 2,234,330 |
| Series C preferred stock subject to settlement | – | – | – | (98,458) | – | – | – | – | – | – | – | – | |
| Preferred stock dividends | – | – | – | 98,458 | – | – | – | (98,458) | – | – | – | – | (98,458) |
| Foreign currency translation adjustment | – | – | – | – | – | – | – | – | – | – | – | 2,587 | 2,587 |
| Net income | – | – | – | – | – | – | – | – | – | – | 746,860 | – | 746,860 |
| Repurchase of common stock | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Balance, January 31, 2026 | – | $– | 4,766 | $872,323 | $417,000 | 26,005,715 | 2,602 | $183,141,663 | (15,270,066) | $(45,009,541) | $(100,000,171) | $(21,540) | $38,113,013 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.